: ANTIBODY GLYCOSYLATION VARIANTS HAVING INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
Application 195/KOLNP/2004 published 2006-04-07, filed 2004-02-13
The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to glycosylation engineering to generate proteins with improved therapeutic properties, including antibodies with increased antibody-dependent cellular cytotoxicity. (FIG.NIL)
Applicant
GLYCART BIOTECHNOLOGY AG
Einsteinstrasse, CH-8093 Zurich, SWITZERLAND.
Inventor
1. JEAN-MAIRET, Joel; 2. UMAÑA, Pablo; 3. BAILEY, James, E.
International Info
Classification: C12N 5/10, 5/12, 5/16, 5/20, 5/24, 9/10, 15/12, 15/13, 15/54, C07K 16/28, 16/30, A61K 39/395
Publication Number: WO 03/011878
Application Date: 2002-08-05
Priority Information
60/309,516 U.S.A. 2001-08-03